Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“(R)-2HG competitively inhibited BCAT1, which is a cytosolic enzyme, with respect to 2OG over a physiologically-relevant range of 2OG concentrations”
From Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma (2018) · cites this paper as Koivunen et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“Though it is found at low levels in normal cells, D-2HG can accumulate to millimolar levels in cancer cells expressing mutant IDH. At these high concentrations, D-2HG can inhibit αKG-dependent dioxygenases, including enzymes involved in histone and DNA demethylation (Chowdhury et al., 2011; Janke et al., 2017; Koivunen et al., 2012; Xu et al., 2011).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Koivunen et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“Although HIF is typically viewed as an oncoprotein it can behave as a tumour suppressor in embryonic stem cell”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradatio”
BackgroundIto, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373 · cited 1×
“Human EGLN1, 2 and 3, collagen P4H-I and FIH, and murine Tet1 and Tet2 were produced in insect cells and purified as described earlie”
MethodAbsolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli
Bennett, B. D., Kimball, E. H., Gao, M., Osterhout, R., Van Dien, S. J., & Rabinowitz, J. D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.186 · Cited by 1,830 · cited 1×
“Studies in model organisms suggest that many metabolic enzymes are saturated in vivo with a mixture of substrate and competitive inhibitors and thus are sensitive to changes in substrate concentrations that are far above their nominal K m value”
BackgroundGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“Nor are our data incompatible with the finding that HIF-1a protein levels are increased in IDH mutant tumours relative to normal brai”
ResultThe oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Cited by
Items 701–752 of 752
Goncalves, J. (2021) · theses.fr (ABES) · doi:10.70675/c8c1e120z2ec7z4009zb20bz9588f2985a48
Impact du R-2HG sur l'environement immunitaire des gliomes IDH1 mutés
Richard, Q. (2022) · theses.fr (ABES) · doi:10.70675/028d6799zbec4z48eez9deaz56fa6f14fd6b
Cognitive Impairment in CNS-Related Cancer Therapy: Focus on Immunotherapy
Safarzadeh, E., Ghorbaninezhad, F., Soleimani, H., Rafiee, R., Mohammadzadeh, R., Azarfarin, M., & Dadkhah, M. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_433
Impact of D-2HG on the Tumor Microenvironment of IDH-mutated Gliomas
Laurenge, A. (2024) · theses.fr (ABES) · doi:10.70675/4c8abeaez46dfz40bdz8c7bzffd11e8e6b36
Molecular drivers in primary brain tumor formation
Richard, H. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.04.006
Lysine-R2HGylation-C5 identified as a post-translational modification in R2HG-elevated cancers
Zhao, Q., Huang, P., Yuan, C., Xia, P., Gu, Q., Yang, T., Li, X., Tian, R., & Yang, D. (2026) · Nature Communications · doi:10.1101/2025.10.03.680013 · Cited by 1
“Finally, we determined the relative configurations of Probe Series 3–5 via chiral derivatization (Scheme 1, Supplementary Schemes 3–6 and Supplementary Figures 1–3), with diastereomeric and enantiomeric purities confirmed using chiral HPLC (Supplementary Information).”
InfluentialArregui, C. D. L. C., Frank, A. R., Mun, K., Kim, J., Majmudar, K., Bishop, J. A., Lewis, C. M., Xie, Y., & McFadden, D. G. (2026) · Science Advances · doi:10.1126/sciadv.aee5417
“We analyzed exome sequencing datasets for regions of homozygosity, and we determined that UT946 Tumor displayed loss of heterozygosity (LOH) across Chr 1 to 4, 6, 8, 9, 11, 14 to 16, and 20 to 22, consistent with widespread LOH previously reported for larger cohorts of OCT tumors (fig.”
Voon, H. P. J., Hii, L. L., Garvie, A., Udugama, M., Krug, B., Russo, C., Chüeh, A. C., Daly, R. J., Morey, A., Bell, T. D. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24779207
Voon, H. P. J., Hii, L. L., Garvie, A., Udugama, M., Krug, B., Russo, C., Chüeh, A. C., Daly, R. J., Morey, A., Bell, T. D. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24779363
Voon, H. P. J., Hii, L. L., Garvie, A., Udugama, M., Krug, B., Russo, C., Chüeh, A. C., Daly, R. J., Morey, A., Bell, T. D. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26651274
Sanghvi, K. (2023) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00033640
Palanisamy, R. (2018) · eScholarship@McGill (McGill) · doi:10.82308/26897
Caractérisation des cellules souches de glioblastomes : nouvelles approches thérapeutiques
Balbous, A. (2014) · theses.fr (ABES) · doi:10.70675/55c03cb5zd67ez4333zb7eaz8bfdc79a51e5 · Cited by 1
Rôle de l'activation de STAT3 dans l'agressivité des glioblastomes. : Cancérologie expérimentale.
Ouedraogo, Z. G. (2014) · theses.fr (ABES) · doi:10.70675/9f4fc9d3zce97z4feaz82e2z02dc42d2e84d · Cited by 1
Mahé, E. A. (2016) · theses.fr (ABES) · doi:10.70675/daf5feb1z2f61z4e8bzb3a6za907fab675b8
Leventoux, N. (2018) · theses.fr (ABES) · doi:10.70675/1b8ddd02z3a93z40cdz9da9z8c69201d9db7
Stage-specific changes in the Krebs cycle network regulate human erythroid differentiation
Romano, M. (2018) · theses.fr (ABES) · doi:10.70675/4312681cz0207z4923zb100z879f8a73681c
Clément, A. (2020) · theses.fr (ABES) · doi:10.70675/20ecced0ze21cz4435z9db3z1e6d2241a888 · Cited by 2
Impact du ciblage du domaine de liaison de HIF-1α avec HIF-1β sur le paysage immunitaire du mélanome
Lequeux, A. (2020) · theses.fr (ABES) · doi:10.70675/a29d12dbz79c1z4d37za978z2e2319131c82
EVT-701 : targeting electron transport chain complex I as therapeutic approach in cancer
Yolba, R. L. (2021) · theses.fr (ABES) · doi:10.70675/9cadea77z03ccz4a54zb381zf34a432615a5 · Cited by 2
Etude de l'hétérogénéité du microenvironnement et des cellules tumorales dans le lymphome TFH
Mboumba, D. L. (2024) · theses.fr (ABES) · doi:10.70675/ab609d7azbd90z40daza2b9za9670f82c1f5
Fonctions mitochondriales de la protéine Optineurine : neurodégénérescence et cancer
D’Urso, B. (2025) · theses.fr (ABES) · doi:10.70675/fe933860ze386z4ca5zaa6fzfcd35c62ce81
2-Hydroxyglutarate in onco-pathway: a metabolic driver of proto-oncogene activation
Thamim, M., Dhabal, D., Balamurali, M. M., & Thirumoorthy, K. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1791517
“Prominent evidence suggests that the uplifted level of 2HG stimulates the tumor microenvironment by sustaining HIF-1 a signaling and modifying immune cell signals, thereby promoting the fi ght against earmark therapies and immunotherapies (147).”
Astrocytoma-Specific Prognostic Associations of Amyloid-Related Biological Processes
Irizarry, F. N., Porter, T. R., Serrano, N. R., & Kucheryavykh, L. Y. (2026) · Pathophysiology · doi:10.3390/pathophysiology33020030
Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular TumorsPreprint
Yu, D.-M., Lee, E. L., Starrett, G. J., Zhai, Z., Dowell, E. M., Walsh, K., Day, A., Palsgrove, D. N., Bishop, J., Marchione, D. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.14.725132
“(23,26,38-40) We provide evidence that low VAF IDH1/2 mutations may exert non-cell-autonomous transforming effects through the secretion of D -2-HG. Consistent with studies in astrocytes(28,41), IDH1/ 2 mutation did not provide endothelial cells with a cell autonomous growth advantage in vitro.”
Zhang, H.-H., Chen, X.-T., Li, S.-Q., Yan, X.-L., Wang, M., Lin, Y., Yuan, Y.-Y., Mao, Y.-Z., Liu, J. Z., & Xu, W. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02988-9
“Specifically, the IDH1 R132H and IDH2 R172H mutants gain the ability to convert α-ketoglutarate (α-KG) into (R)-2-hydroxyglutarate (R-2-HG) [1], a biochemical reaction otherwise typically observed in bacteria.”
Label-Free Live Cell Type Prediction by Integrating Raman Spectroscopy and Machine LearningPreprint
Lita, A., Zannat, N. E., Muley, H., Siminea, N., Spinu, S., Sjöberg, J., Păun, A., Nikulin, Y., Herold‐Mende, C. C., Petre, I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.16.732770
“One of the most striking observations was the prominence of cytochrome c-associated 40,41,43,46,49,50,53 .”
Targeted therapy in recurrent clival chordoma: a case report of response to ivosidenib
Rahbarlayegh, E., & Kesari, S. (2026) · The Oncologist · doi:10.1093/oncolo/oyag240
Jiang, L., Li, M., Li, Z., Liu, Q., & Li, Y. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71180
“IDH1/2 mutations define major adult diffuse glioma subtypes and generate D-2HG, thereby reshaping epigenetic regulation, redox balance, and metabolic dependencies [39, 54–57].”
Diksin, M. A. M. (2021) · Nottingham ePrints (University of Nottingham)
BindingDB (2019) · UC San Diego · doi:10.7270/q2bc41z0
BindingDB (2013) · UC San Diego · doi:10.7270/q26q1zjv
Song, D., Wang, Y., Li, B., Liu, Y., Guo, P., Mi, Y., Qu, H., Nie, S., Jiang, Y., Song, Y., et al. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e01114
Emerging Anti-cancer Targets in Mitochondria
Ježek, P., Smolková, K., Dvořák, A., & Olejár, T. (2014) · Springer eBooks · doi:10.1007/978-94-017-8984-4_10
The Dual Role of HIF Hydroxylase PHD3 in Cancer Cell Survival
Rantanen, K. (2012) · UTUPub (University of Turku)
Metabolic Adaptation in Reprogrammed Cancer Cells
Marks, K. M., & Kung, C. K.-H. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9545-1_7 · Cited by 1
Metadata
- Authors
- Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., Travins, J., Weiss, S., Looper, R., Ligon, K. L., Verhaak, R. G. W., Yan, H., & Kaelin Jr, W. G.
- Affiliations
- University of Oulu (FI)
- Brigham and Women's Hospital (US)
- Duke University (US)
- Agios Pharmaceuticals (United States) (US)
- University of Calgary (CA)
- University of Utah (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 484-488
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656605
- OpenAlex
- W2142898716
- Cited by
- 727
- References
- 41
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 38 · 2023: 32 · 2022: 35 · 2021: 44 · 2020: 56 · 2019: 52 · 2018: 66 · 2017: 63 · 2016: 61 · 2015: 57 · 2014: 70 · 2013: 59 · 2012: 43
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA140316)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- R-enantiomer, IDH1 mutation, IDH2 mutation, hypoxia-inducible factor, glioma, astrocyte proliferation, oncometabolites, cancer metabolism, histone demethylation, DNA hypermethylation, CpG island methylator phenotype
- MeSH terms
- Astrocytes, Cell Line, Cell Transformation, Neoplastic, Enzyme Activation, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Nuclear Proteins, Oncogenes, Procollagen-Proline Dioxygenase, Cell Line, Tumor, Cell Proliferation, Dioxygenases, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.